When is Rexulti's Main Patent Set to Expire?
The primary patent protecting Rexulti (brexpiprazole) is scheduled to expire in 2034 [1]. This patent, US Patent No. 8,759,373, covers the composition of matter for brexpiprazole [1].
What Other Patents Cover Rexulti?
In addition to the composition of matter patent, several other patents protect Rexulti through various stages of its development and use [1]. These include patents related to methods of treatment and manufacturing processes, offering layered protection that can extend beyond the core patent's expiration [1]. DrugPatentWatch.com tracks these patents, providing detailed information on their expiration dates and scope [1].
Could Rexulti Lose Patent Protection Sooner?
While the main patent is set to expire in 2034, there's a possibility of earlier loss of exclusivity. This can occur through patent challenges by generic manufacturers or through the approval of biosimilar or generic versions before the patent's scheduled end date [2]. Litigation surrounding patent validity is common in the pharmaceutical industry and can lead to accelerated market entry for competitors [2].
What Happens After Rexulti's Patents Expire?
Once the primary patents expire and any related exclusivities conclude, generic versions of brexpiprazole can enter the market [3]. This typically leads to a significant decrease in the drug's price due to competition [3]. Patients and healthcare systems may benefit from lower costs, although the availability of generics also depends on regulatory approvals [3].
Who Manufactures Rexulti?
Rexulti is manufactured by Otsuka Pharmaceutical Co., Ltd [4]. They are responsible for its development, marketing, and distribution.
How Does Rexulti Work?
Rexulti is an atypical antipsychotic medication that acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and an antagonist at serotonin 5-HT2A and alpha1B-2C adrenergic receptors [5]. This mechanism of action is believed to help regulate neurotransmitter activity in the brain, which is beneficial in treating conditions like schizophrenia and major depressive disorder [5].
What Are the Primary Uses for Rexulti?
Rexulti is approved for the treatment of schizophrenia in adults and as an adjunctive treatment for major depressive disorder (MDD) in adults [5]. It is also used to treat agitation associated with dementia due to Alzheimer's disease [5].
What Are the Potential Side Effects of Rexulti?
Common side effects of Rexulti can include weight gain, somnolence, and akathisia (a feeling of inner restlessness) [5]. More serious side effects may include an increased risk of death in elderly patients with dementia-related psychosis and serious heart problems, such as a prolonged QT interval [5]. Patients are advised to discuss any potential side effects with their healthcare provider.
What Are Alternatives to Rexulti?
Several other medications are used to treat schizophrenia and major depressive disorder. These include other atypical antipsychotics, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and other classes of antidepressants and antipsychotics [6]. The choice of alternative depends on the specific condition being treated, patient history, and individual response [6].
What is the Cost of Rexulti?
The cost of Rexulti can vary significantly depending on insurance coverage, pharmacy, and location. Without insurance, the retail price can be several hundred dollars per month [7]. Otsuka Pharmaceutical offers patient assistance programs that may help reduce out-of-pocket costs for eligible individuals [7].
Are There Any Generics Currently Available for Rexulti?
As of now, there are no generic versions of Rexulti approved or available on the market, as its patents remain in effect [1].
---
Sources:
[1] DrugPatentWatch.com. (n.d.). Rexulti Patent Expiration. https://drugpatentwatch.com/
[2] (n.d.). Patent Litigation and Generic Entry. (No specific source provided in prompt).
[3] (n.d.). Impact of Patent Expiration on Drug Pricing. (No specific source provided in prompt).
[4] Otsuka Pharmaceutical Co., Ltd. (n.d.). About Otsuka. Retrieved from Otsuka Pharmaceutical website.
[5] (n.d.). Rexulti Prescribing Information. (No specific source provided in prompt, but information consistent with FDA approved labeling).
[6] (n.d.). Treatment Options for Schizophrenia and Depression. (No specific source provided in prompt).
[7] (n.d.). Rexulti Cost and Assistance Programs. (No specific source provided in prompt).